Clinical outocomes and therapy of polyploid DLBCL and control DLBCL.

<p>Clinical outocomes and therapy of polyploid DLBCL and control DLBCL.</p

Immunohistochemistry analysis and chromosomal translocation abnormalities.

<p>Immunohistochemistry analysis and chromosomal translocation abnormalities.</p

Univariate and multivariate analysis for overall survival in DLBCL.

<p>Univariate and multivariate analysis for overall survival in DLBCL.</p

Analysis of immunohistochemistry staining in polyploid DLBCL.

<p>Tumor cells were positivity in each immunohistochemistry. CD5 (X400), (B) CD10 (X400), (C) CD30 (X400), (D) BCL2 (X400), (E) BCL6 (X400) and (F) MUM1 (X400).</p

Histology of polyploid diffuse large B-cell lymphoma (DLBCL).

<p>(A) HE staining, large tumor cells (black arrows). (B) Tumor cells were positive for CD20. (C) HE staining, multilobated tumor cells (black arrows) with many apoptotic cells (arrow heads). (D) Tumor cells were positive for CD20. (E) HE staining, multilobated medium-sized cells (black arrows). (F) Tumor cells were positive for CD20.</p

Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 45) and control DLBCL, NOS (n = 42) patients in only cases who received R-CHOP regimens.

<p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<i>p</i> = 0.02). (B) The progression-free survival curves were not significantly different between polyploid DLBCL and control DLBCL (<i>p</i> = 0.27).</p

Clinical features of polyploid DLBCL and control DLBCL.

<p>Clinical features of polyploid DLBCL and control DLBCL.</p

Overall survival and progression-free survival between polyploid DLBCL, NOS (n = 51) and control DLBCL, NOS (n = 53) patients.

<p>(A) The overall survival curves were significantly worse for polyploid DLBCL than control DLBCL (<i>p</i> = 0.04). (B) The progression-free survival curves were not significantly different between the polyploid DLBCL and control DLBCL (<i>p</i> = 0.49).</p